Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

July 15, 2024

Study Completion Date

July 31, 2026

Conditions
Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMixed Phenotype Acute LeukemiaUndifferentiated LeukemiaMyelodysplastic SyndromeAcute LeukemiaTherapy-Related Myelodysplastic Syndrome
Interventions
BIOLOGICAL

Orca-T

an allogeneic stem cell and T-cell immunotherapy biologic

BIOLOGICAL

Standard-of-Care

unmanipulated donor allograft

Trial Locations (19)

10021

Weill Cornell Medicine - New York-Presbyterian Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

30322

Winship Cancer Institute - Emory University, Atlanta

33136

University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center, Miami

33612

Moffitt Cancer Center, Tampa

37232

Vanderbilt University, Nashville

37239

Sarah Cannon Research Institute, Nashville

44195

Cleveland Clinic, Cleveland

48109

University of Michigan Health System - Michigan Medicine, Ann Arbor

60637

University of Chicago, Chicago

73104

OU Health Stephenson Cancer Center, Oklahoma City

80218

Colorado Blood Cancer Institute, Denver

84112

University of Utah, Salt Lake City

90095

Ronald Reagan UCLA Medical Center, Los Angeles

91010

City of Hope, Duarte

94305

Stanford Health Care, Stanford

95817

UC Davis, Sacramento

97239

Oregon Health & Sciences University - Knight Cancer Institute, Portland

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Orca Biosystems, Inc.

INDUSTRY